The first phase, from 2020 to 2025, would be structured to build the foundation for a concerted global effort, and would aim to collect, characterize and make available existing pharmacological modulators for key representatives from all proteins families in the current druggable genome (~4,000 proteins), as well as to develop critical and centralized infrastructure to facilitate data collection, curation, dissemination, and mining that will power the scientific community worldwide. This phase might also create centralized facilities to provide quantitative genome-scale biochemical and cell-based profiling assays to the federated community, as well as to coordinate the development of new technologies to extend the definition of druggability. This first phase will complement and extend ongoing efforts to create chemical tools and chemogenomic libraries to blanket priority gene families, such as kinases and epigenetics families.
One year into Target 2035 has so far yielded infrastructure to house [https://gateway.eubopen.org/ data] on chemogenomic compounds reported in the literature. A progress update was published recently. Towards the development of new technologies, Target 2035 started a new initiative [https://www.cache-challenge.org/ Critical Assessment of Computational Hit-Finding Experiments] (CACHE) aimed at benchmarking computational methods for hit-finding. The first [https://www.cache-challenge.org/competitions/competition-1 competition] - finding ligands for the WD40 domain of LRRK2 - started in March 2022. The first round of predictions have been submitted. In the meantime, applications for the second CACHE benchmarking - [https://www.cache-challenge.org/challenges/finding-ligands-targeting-the-conserved-rna-binding-site-of-sars-cov-2-nsp13 predicting ligands for the RNA-binding domain for Nsp13] - has been posted.